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Abstract 
 
Parametric Contrast Enhanced Ultrasound Evaluation of Transarterial 
Chemoembolization  
Minakshi Mohanty 
Flemming Forsberg, PhD and Peter Lewin, PhD 
 
This work investigates quantitative contrast enhanced ultrasound (CEUS) derived blood 
flow parameters for evaluating chemoembolization of hepatocellular carcinoma. 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide 
and is becoming increasingly common. Liver transplant is the only cure with 70 percent 5 
year survival rate. However, transplant requires the tumor to fall under the Milan criteria 
(less than 5cm or up to 3 nodules each less than 1cm) and the technique is limited by the 
availability of donors. Transarterial chemoembolization (TACE), currently, is a treatment 
option for non-resectable tumors. It involves the administration of drug eluting beads via 
catheter into the branch of the hepatic artery that feeds the tumor. These beads occlude the 
blood supply to the tumor and at the same time release chemotherapy, leading to necrosis 
of the tumor and reduction in its size. Presently, the effectiveness of TACE procedure is 
determined one month post embolization through the use of contrast enhanced magnetic 
resonance imaging (MRI) or computed tomography (CT) scans, by evaluating blood flow 
within the tumor. Early screening for effective chemoembolization with contrast-enhanced 
MRI has been proven ineffective due to an inability to adequately visualize the vasculature. 
An earlier estimation of treatment efficacy would provide clinicians more time and options 
for re-treatment. Additionally, a number of patients may have morbidities including renal 
insufficiency. These patients may develop nephrogenic systemic fibrosis, which is the 
xvi 
 
necrosis of skin and the internal organs, on exposure to gadolinium (present in MRI 
contrast agents).  
 
This project proposes the use of contrast enhanced ultrasound (CEUS) for monitoring the 
effectiveness of transarterial chemoembolization. Ultrasound contrast agents are gas filled 
microbubbles, which are encapsulated within a thin elastic shell made of lipids. They have 
a diameter of 1-10µm. Due to their restriction to the vasculature, an absence of contrast 
within the tumor is expected in cases where complete embolization has been achieved. 
Earlier studies have shown that lack of detected agents as little as 2 days post procedure 
correlated with effective procedure. However, currently there is no established standard as 
to how many days post treatment should the follow up be conducted, or which contrast 
agent to use.   
Fourteen patients with 16 lesions scheduled for transarterial chemoembolization (TACE) 
of HCC using drug eluting beads provided informed consent to undergo  CEUS exam prior 
to treatment, 2 weeks post treatment, and the morning of follow up (contrast enhanced MRI 
1 month post TACE). Ultrasound was performed using a Sequoia 512 scanner with 4C1 
probe (Siemens Medical Solutions, Mountain View, CA). CEUS data was acquired using 
Cadence Pulse Sequencing (Siemens) during bolus injection of 0.6-0.7 ml of Definity 
(Lantheus Medical Imaging, N. Billerica, MA). Motion compensation was performed and 
time intensity curves were generated on a pixel-by-pixel basis to create parametric images 
showing maximum signal intensity (MAX), time to peak intensity (TTP), perfusion (PER), 
and area under curve (AUC). These values were averaged over the tumor and expressed 
xvii 
 
normalized relative to baseline. Results were then grouped by clinical diagnosis (fully 
treated (n=5), partially treated (n=5) or no change (n=6)) and compared at each time point.  
Parametric imaging was successfully performed on 10 lesions, while six were excluded 
due to inability to identify tumor. Significant difference was observed in the time to peak 
dataset 2 weeks post TACE between complete response and no response group (p=0.018). 
No significance was observed in maximum intensity, perfusion and area under curve 
dataset. In the time intensity parameters obtained 4 weeks post TACE, no significant 
difference was observed.  
In conclusion, time to peak currently appears to be a good quantitative CEUS parameter 
for evaluating the effectiveness of TACE treatment 2 weeks post treatment.
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1. INTRODUCTION 
 
1.1 An Overview 
 Liver is a vital organ of the human body. It is located in the upper right quadrant of the 
abdomen, below the diaphragm [1]. The liver consists of four lobes and receives its blood 
supply from hepatic artery and portal vein. The hepatic artery supplies the liver with 
oxygenated blood from the heart and the portal vein brings in nutrient rich blood from the 
intestines [2]. Liver is made up of two kinds of cells: parenchymal cells and non-
parenchymal cells. Parenchymal hepatocytes constitute about 75% of the liver volume. 
Non-parenchymal cells occupy about 6.5% of the liver volume [1].  
The functions of the liver include: 
 Breaking down and storage of nutrients absorbed form the intestines. Many 
nutrients need to be broken down into simpler forms by the liver before they can 
be used by the rest of the body. 
 Liver secretes bile into the intestines that help in the absorption of nutrients. 
 Detoxify or excrete drugs such as penicillin, ampicillin and erythromycin.  
 Forms blood substances, fibrinogen, prothrombin, accelerator globulin, factor VII, 
used in coagulation. 
 Storage site for vitamin A, d and B12 and iron in the form of ferritin [3]. 
Hepatocelluar carcinoma is the most common form of liver cancer. It begins in the liver 
cells, called hepatocytes. In about 70-90% of cases, hepatocellular carcinoma develops as 
a result of chronic liver disease [4]. These may include infection from Hepatitis B or 
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Hepatitis C virus, cirrhosis of the liver and excessive alcoholism. It is the third leading 
cause of cancer mortality worldwide. The survival rate one year after diagnosis is less than 
50% [5]. Liver transplantation is the only cure for HCC with 70% 5 year survival rate [6]. 
Liver transplant is possible only for tumors that fall under the Milan criteria (1 lesion less 
5cm or up to 3 nodules less than 3cm) [7]. Liver transplantation is limited by the availability 
of donors [8]. About 30% of referred patients are eligible for surgical resection.  The 5 year 
recurrence rates for this group is higher than 50% [9]. 
In patients with non-resectable tumors, chemoembolization has shown to be an effective 
measure to reduce tumor progression. In the process, anti-cancer drugs are administered 
directly to the tumor via catheter and the blood supply to the tumor is subsequently 
obstructed using embolization materials such as gelfoam [10]. Drug eluding beads are 
being used by many clinicians to provide gradual and sustained delivery of 
chemotherapeutic after embolization. Currently, the effectiveness of this procedure is 
determined, by evaluating the blood flow within the tumor, one month post treatment 
through the use of contrast enhanced MRI scans. An earlier method to evaluate the efficacy 
of the treatment would provide increased treatment options, in turn better patient outcomes. 
Additionally, a number of patients who have morbidities including renal insufficiency, 
This study proposes the use of contrast enhanced ultrasound as a follow up method to 
evaluate the efficacy of TACE treatment at an earlier timeframe. Ultrasound contrast agents 
are gas filled microbubbles that are encapsulated by a lipid shell to provide stability. The 
diameter of these bubbles lie in the range of 1-10 µm [11]. Because of their small size, they 
are capable of passing through the pulmonary capillaries, and at the same time be restricted 
to the vascular system [11]. These microbubbles have been approved for the purpose of 
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echocardiography in the United States and also for the characterization of liver lesions 
throughout Europe and Asia [12].  
 
1.2 Thesis Objective 
Primary Aim: To investigate quantitative contrast enhanced ultrasound (CEUS) derived 
blood flow parameters for evaluating chemoembolization of hepatocellular carcinoma 
(HCC). 
Transarterial chemoembolization procedure aims at blocking the tumor vascularity, and 
providing gradual and steady dose of chemotherapy to induce tumor necrosis. The efficacy 
of this procedure is monitored using contrast enhanced MRI scan 4 weeks post TACE. The 
aim of this study is investigate if CEUS derived blood flow parameters can be used as a 
follow up method to evaluated TACE, instead of MRI. Parametric images are generated to 
show maximum intensity, time to peak, perfusion and area under curve for each pixel in 
the image throughout the time sequence. These parameters are analyzed to determine if 
they correlate with effective chemoembolization. 
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2. BACKGROUND AND LITERATURE REVIEW 
 
 
This chapter presents the background information and literature review related to liver 
anatomy, hepatocellular carcinoma, its treatment using transarterial chemoembolization 
and the follow up procedure. This chapter also discusses the potential use of contrast 
enhanced ultrasound to predict the efficacy of the treatment and compare it to the current 
clinical imaging choices. 
 
2.1 Liver Anatomy 
The liver is the second largest organ in the human body [2]. It is located in the upper right 
quadrant of the abdomen, below the diaphragm [1]. It is a solid organ weighing about 1.5 
kg [13].  The liver consists of four lobes, left, right, caudate and quadrate lobe [3]. The 
liver has dual blood supply. It receives about 25% of the total blood supply from the hepatic 
artery and the rest 75% from the portal vein. The hepatic artery supplies oxygenated blood 
directly from the systemic arterial system whereas, the portal vein provides partially 
deoxygenated blood via the bowel, spleen and other viscera [3].  
The liver performs different types of functions. These include metabolism of 
carbohydrates, fats and proteins, maintaining blood glucose level, filtering out toxins and 
regulating hormonal balance. The liver acts as a storage site for vitamins A, B12, and D. It 
stores iron in the form of ferritin. The liver forms the blood substances used in coagulation 
[3]. 
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2.2 Hepatocellular Carcinoma  
Hepatocellular carcinoma is the most common type of liver cancer. It develops in the liver 
cells called hepatocytes. HCC is the third leading cause of cancer mortality worldwide [5]. 
American Cancer Society estimates 35,660 new cases of liver cancer in USA in 2015, 
three-fourths of which will be HCC [1].The primary risk factors of HCC are Hepatitis B 
virus, Hepatitis C virus and cirrhosis of the liver. The underlying cause of HCC cases 
differs from one geographical location to another. Eastern Asia and sub- Saharan Africa 
have the most cases of hepatocellular carcinoma, where the leading risk factor is chronic 
infection with hepatitis B virus, along with exposure to aflatoxin B [7]. In North America, 
Europe and Japan, the dominant risk factor is hepatitis C virus, together with alcoholism 
[7].  
The symptoms of HCC include jaundice, fatigue, upper abdominal pain, nausea, and 
vomiting, unintentional weight loss, loss of appetite and abdominal swelling [15]. 
 
2.3 Treatment Methods 
Treatment of HCC depends on the stage of the disease, along with the patient’s age, and 
overall health. The Barcelona Clinic Liver Cancer (BCLC), the four stages of the disease 
are: 
 Early stage (A): It is also known as the Milan criteria. Asymptomatic single tumor 
5cm or 3 nodules, each less than or equal to 3cm 
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 Intermediate stage (B): these include patients with tumors that exceed early criteria 
but do not show cancer related symptoms, vascular invasion or metastases. 
 Advanced stage (C): patients with mild cancer-related symptoms, vascular invasion 
or extrahepatic spread. 
 End- stage (D): patients with advanced, symptomatic disease [16].  
The treatment methods include surgical resection, liver transplantation, and image-guided 
tumor ablation.  
 
2.3.1 Surgical Resection 
Surgical resection involves removal of all or a part of the liver. This procedure is mostly 
restricted to patients with solitary HCC without vascular invasion or extra hepatic spread. 
It is more favorable for patients without cirrhosis, as they are capable of tolerable major 
resections with low rates of complications [7]. A tumor diameter of ≤ 5cm is used as a cut 
off limit for surgical resection. Larger tumors will have more nodules, making incomplete 
resection or early recurrence of disease more likely [17]. High serum bilirubin level and 
significant portal hypertension (≥ 10 mm Hg) is an indication of hepatic decompensation 
[17]. Therefore, only patients with normal bilirubin level and no portal hypertension should 
be considered for resection, as they will not present relevant functional impairment. Only 
30% of the referred patients are eligible for surgical resection and this group is still plagued 
by 5 year recurrence rates higher than 70% [9]. 
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2.3.2 Liver Transplantation 
Theoretically, a liver transplantation can cure both the cancer as well as the underlying 
cirrhosis simultaneously. The success of the treatment will not depend on the extent of liver 
function impairment [7]. Patients with cirrhosis are selected for liver transplant based on 
the Milan criteria. The Milan criteria includes HCC of 5cm or less, or up to three nodules 
of 3cm of less, without vascular invasion or extra hepatic spread [7]. A study conducted by 
Mazzaferro and colleagues showed that patient who met the Milan criteria had a 4-year 
survival of 75% with a recurrence rate of less than 15% [7]. These results were feasible in 
an era with quick availability of donor organs. The shortage of donor imposes a delay in 
the treatment, during which the tumor may progress, reducing the effectiveness of a liver 
transplant. If the waiting period exceeds six months, treatments such as ablation, or 
chemoembolization may be performed to delay tumor progression. Transplantation 
policies may vary from country to country, but generally are implemented to give priority 
to the sickest patients. Live donations have shown similar results to that of cadaveric 
donations, but its application is limited due to societal constraints and thus, a scarcity of 
appropriate donors [7]. 
 
2.3.3 Image guided tumor ablation 
Image guided tumor ablation is a treatment option for patient with early stage (stage A) 
HCC.  Ablation is the process of inducing tumor necrosis using chemicals, such as ethanol, 
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acetic acid, or by modifying the temperature using radiofrequency, microwave, laser, high-
intensity focused ultrasound or cryoablation [7, 18].  
The principle of radiofrequency ablation involves conversion of electromagnetic energy 
into heat. The equipment used consists of a generator that converts energy produced by 
alternating current of 90Hz in to radiofrequency band of 500 kHz [19]. The current is linked 
to an active electrode in the form of a needle that is inserted into the tumor. The current is 
dispersed with a passive electrode in the form of a plate, placed on the skin of the patient. 
The tissue surrounding the needle opposes the flow of current. This resistance generates 
heat causing tumor tissue necrosis [19].  
In case of tumor size less than 2cm, both radiofrequency ablation and ethanol injection 
achieve almost complete necrosis. However, the efficacy of treatment with ethanol 
injection decreases in large tumors. Radiofrequency ablation may still be effective in larger 
tumors. Ablation is not recommended if the tumor size exceeds 5cm [7].  
High-intensity focused ultrasound (HIFU) is also an ablation technique for treatment of 
liver cancers. The primary therapeutic mechanism of this technique is the deposition of 
thermal energy by a focused ultrasound beam. A high power transducer generates the 
ultrasound beam. The transducer employed is phased array and bowl- shaped. This helps 
achieve focalization of the ultrasound beam. The HIFU beam is focused onto the tissue that 
needs to be ablated. The beam passes through the skin and other soft tissues without causing 
any damage. But, the tissue present in the focal region of the HIFU beam absorbs 
significantly more acoustic energy, in comparison to its surrounding area. This results in 
an increase in temperature which causes localized coagulation necrosis. The adjacent areas 
remain unharmed in this procedure. Image guidance is provided by magnetic resonance 
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imaging. Thus this technique is referred to as magnetic resonance guided high-intensity 
focused ultrasound (MR-HIFU). Unlike ablation using RF, MR- HIFU does not require 
insertion of probe into the body. Thus, it is a completely non-invasive technique. MR-HIFU 
also does not rely much on thermal conduction, as the entire ablation volume is directly 
heated by the deposited ultrasound energy [18].  
 
2.3.4 Transarterial Chemoembolization 
Transarterial chemoembolization (TACE) is typically used to treat patients with non-
resectable tumors. A normal liver has dual blood supply, 75% by the portal vein and 25% 
by the hepatic artery. Liver tumors are predominantly supplied by hepatic artery. This 
feature makes it possible to deliver localized treatment to tumors and at the same time limit 
the toxicity to uninvolved adjacent parenchyma [20]. Chemoembolization involves the 
direct infusion of anti-cancer drugs followed by occlusion of tumor vasculature using an 
embolization material [10]. In this process the tumor vasculature is accessed using a 
catheter through the hepatic artery. A catheter is inserted into the femoral artery and 
advanced until it reaches the common hepatic artery. Once the catheter is accurately 
positioned, the tumor is visualized by performing an angiogram. Beads containing 
chemotherapy drug are injected into the catheter and released inside the feeder vessel. 
These beads block the blood supply to the tumor and also begin a controlled release of 
chemotherapy causing shrinkage and necrosis of the tumor. It has been shown that patients 
with stage 3 or stage 4 HCC can be down staged using chemoembolization to a point where 
chemoembolization can take place [21].  TACE has shown to be an effective measure not 
just to slow down tumor progression but also improve patient response with less toxicity 
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[22, 23]. LC beads (Biocompatibles UK Ltd) consists of poly-vinyl alcohol hydrogel with 
modified sulfonate groups for attachment of anthracycline drugs (doxorubicin). 
Embolization using LC beads result in obstruction of the tumor vasculature as well as 
gradual, sustained and intratumoral release of chemotherapy [24].  
Currently, the effectiveness of the TACE procedure is decided four weeks post 
embolization by evaluating blood flow inside the tumor using contrast- enhanced MRI [25]. 
Contrast enhanced MRI has been established as the clinical standard imaging modality in 
these patients. Early screening of the tumor to predict the efficacy of the treatment has been 
proven ineffective, due to an inability to visualize the vasculature [26]. Additionally, a 
number of patients have morbidities including renal insufficiency. These patients may 
develop nephrogenic systemic fibrosis, which is the necrosis of skin and the internal 
organs, on exposure to gadolinium (present in MRI contrast agents). 
Thus, an alternative technique that does not use metallic contrast and can also access the 
effectiveness of the treatment in less than one month would greatly benefit this patient 
population. The use of contrast enhanced ultrasound for the purpose of evaluation of TACE 
effectiveness is proposed in this study.  
 
2.4 Ultrasound contrast agents 
Ultrasound contrast agents are made up of high molecular weight gas-filled microbubbles. 
They have a diameter of 1-10µm. They are encapsulated within a thin elastic shell which 
is made up by lipid, fatty acid, protein, or polymers helps to maintain the stability of the 
microbubbles in the human body. Due to their small size, they can mimic the red blood 
cells and enter the capillary network [11]. Ultrasound contrast agents can be injected 
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intravenously as a bolus or as a constant infusion by using a pump.  These contrast agents 
have approximately 17,000-fold more compressibility than water, and hence they can 
strongly scatter ultrasound waves.  An improvement of about 15-25 dB can be achieved in 
the signal-to-noise (SNR) ratio of the ultrasound image, thus increasing the sensitivity of 
this imaging mode [27, 28].  
 
A microbubble undergoes alternate phases of compression and rarefaction when insonified 
by an ultrasound wave. This brings about a change in the size of the microbubble. In the 
positive half of the cycle, the size of the microbubble decreases and in the negative half, it 
increases. This behavior of microbubbles depends on the frequency of the incident 
ultrasound wave and the acoustic pressure amplitude [29]. The compression and expansion 
of the microbubbles are however not exactly equal. This results in asymmetrical and 
nonlinear bubble oscillations [30]. 
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Figure 2.1: Acoustic nonlinear response of contrast agent microbubbles. Reproduced from [31] 
 
There are a number of ultrasound contrast agents that are available in the market. Table 2.1 
summarizes a list of ultrasound contrast agents, their composition and their availability. 
 
Table 2.1: List of Commercially Available Ultrasound Contrast Agents. Reproduced from [32] 
Name Manufacturer Year Gas Coating Availability 
Echovist Schering AG 1991 Air Galactose Off market 
Albunex Molecular 
Biosystems 
1994 Air Human 
Albumin 
Off market 
Levovist Bayer Shering 
Pharma AG 
1996 Air Galactose Off market 
Optison GE Healthcare 1997 C3F8 Human 
Albumin 
EU, USA 
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Definity Lantheus 
Medical 
Imaging 
2001 C3F8 Phospholipids Worldwide 
Sono-Vue 
or Lumason 
Bracco SpA 2011 SF6 Phospholipids Europe, 
South 
Korea, 
China, 
India, Hong 
Kong, 
Singapore, 
USA 
Imagent Alliance 
Pharmaceutical 
2002 C6F14 Phospholipids Off market 
Sonazoid GE Healthcare 2006 C4F10  Japan, South 
Korea, 
Norway and 
China 
 
As discussed in section 1.2, the aim of the study is not only to evaluate if CEUS of HCC 
at one to two weeks and one month post TACE, correlate with the clinical evaluation 
standard of a contrast-enhanced MRI at one month, but also, to establish whether changes 
in blood flow parameters relative to baseline correlate with effective embolization. For the 
purpose of this evaluation, the CEUS data is subjected to motion compensation. Motion 
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compensation is based on Maximum Intensity Projection (MIP) algorithm which is 
discussed in section 2.5. 
 
2.5 Maximum Intensity Projection (MIP) Algorithm 
MIP algorithm is a reconstruction technique that performs one-to-one mapping of the 
pixels with maximum intensity from corresponding locations in all frames onto the final 
reconstructed image [33]. Figure 2.2 shows a schematic of MIP algorithm to produce MIP 
images. In the figure, the three dimensional structure can be considered as the object to be 
scanned. During scanning, the contrast agent flows through the two blood vessels in the 
object. The direction of flow is indicated by white dash lines. The scan data contain frames 
from the 1st to the nth frame. To produce the final image, show at the bottom of figure, the 
MIP algorithm uses the following equation. 
 
Final image (i , j) = max(Frame1(i, j), Frame2(i, j),…… Framen(i, j)) ; ˅(i=1:a, j=1:b)  
(2.1) 
Where,  
a: number of rows in each frame 
b: number of columns in each frame 
(i, j): pixel location 
N: total number of frames [34] 
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Figure 2.2: Schematic of MIP to produce MIP images. Reproduced from [34] 
  
Post motion compensation, the CEUS data is subjected to parametric imaging, where the 
time-intensity curve parameters are extracted. Section 2.6 discusses time-intensity curve 
and parameters in details. 
 
2.6 Time – Intensity curve  
The time intensity curve is a plot of signal intensity over time after the administration of 
contrast agent. Arrival time (AT) is the first point of the curve clearly above the baseline 
intensity, which is followed by further rise in the intensity. Time to peak (TTP) is the time 
from the contrast agent injection to the point at which maximum intensity is reached for 
each individual pixel. Perfusion (PER) is defined as the slope of the rise of the curve from 
10% to 30% of the maximum. This not an accurate representation of the perfusion on pixel 
level due to the presence of noise. A modified definition of perfusion is defined as the slope 
of the curve from the time of contrast arrival to the peak intensity. Area under curve (AUC) 
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is defined as the area under the time – intensity curve from contrast arrival to peak intensity 
[35].  
 
Figure 2.3: Time-intensity curve and the parameters Arrival time (AT), time to peak (TTP), 
perfusion (PER) and area under curve (AUC). Reproduced from [35] 
 
  
PER 
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3. MATERIALS AND METHOD 
 
Fourteen patients with 16 lesions scheduled for transarterial chemoembolization (TACE) 
of hepatocellular carcinoma using drug eluding beads signed informed consent to undergo 
contrast enhanced ultrasound (CEUS) exam prior to treatment, 2 weeks post treatment and 
one month post treatment (on the day of contrast enhanced MRI). The ultrasound exam 
was performed using a Sequoia 512 scanner with 4C1 probe (Siemens Medical Solutions, 
Mountain View, CA). CEUS data was acquired using Cadence Pulse Sequencing 
(Siemens) during bolus injection of 0.6-0.7ml of Definity (Lantheus Medical Imaging, N. 
Billerica, MA). Motion compensation and parametric imaging was performed on the CEUS 
data. Time –intensity curves were generated on a pixel-by-pixel basis to create parametric 
images that show maximum signal intensity (MIP), time to peak intensity (TTP), perfusion 
(PER) and area under curve (AUC). Results were grouped based on MRI findings and were 
compared using ANOVAs. 
 
3.1 Materials 
3.1.1 Ultrasound Contrast Agent 
The ultrasound contrast agent Definity (Lantheus Medical Imaging, N Billerica, MA) was 
used for all imaging procedures throughout the study. Definity is a sterile non-pyrogenic 
suspension of liposome-encaspsulated perfluoropropane microbubbles [28, 36]. The 
contrast is composed of three phospholipids contained in a matrix of sodium chloride, 
propylene glycol and glycerine in water. Definity is supplied in a vial that contains 
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phospholipids and perfluoropropane gas. Table 3.1 gives a summary of the microsphere 
size distribution. 
Table 3.1: Microsphere size distribution [37] 
 Microsphere particle size parameters 
  
Mean diameter range 1.1 µm – 3.3 µm (in vitro measurement) 
  
Percent less than 10 µm 98% 
  
Maximum diameter 20 µm 
  
 
The contrast agent is available as a single use in 2ml glass vial containing clear liquid. It is 
activated by allowing it to warm up to room temperature and then by shaking the vial with 
the aid of shaking device (Vialmix : ESPE, Seefeld, Germany). This provides an opaque, 
homogeneous, milky suspension of liquid microspheres (1.2 x 1010 microspheres/ml and 
150µl octofluoropropane/ml) that can be injected intravenously [37]. Definity is FDA-
approved in the United States of America for use with echocardiography.  
 
3.1.2 Imaging Equipment 
Ultrasound scans were performed using Sequoia 512 scanner with a 4C1 probe. (Siemens 
Medical Solutions, Mountain View, CA). The 4C1 transducer has a frequency bandwidth 
of 1-4MHz [38]. CEUS data was acquired using Cadence™ Pulse Sequencing (Siemens). 
It is a low-power multipulse technique where three pulses with varied phase and amplitude 
are transmitted and the resulting echoes are summed. CPS imaging results in considerable 
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tissue suppression, allowing for better detection of the contrast microbubbles. CPS should 
be used at low mechanical index in order to prevent bubble destruction [39]. 
 
3.2 Data Acquisition from Patients 
14 patients with 16 lesions participated in the study. The participants signed a written 
consent and were approved to take part in the study by the Thomas Jefferson University 
Hospital’s Institutional Review Board. The enrolled patients were scheduled for 
transarterial chemoembolization with drug eluding beads for the treatment of 
hepatocellular carcinoma. These patients first received a CEUS exam prior to treatment. 
Post treatment, CEUS exams were conducted 2 weeks post TACE and one month post 
TACE during MRI follow up. During each exam, grayscale B-mode, power Doppler and 
CEUS of the tumor were performed. At first, a standard ultrasound examination (without 
contrast) was performed to locate the liver mass and obtain information regarding its shape, 
shape and ultrasound characteristics. On completion of the standard exam, the patient 
received a bolus injection of 0.6-0.7ml of Definity through an IV catheter (typically in the 
antecubital vein), followed with a slow flush of 10ml of normal saline. CEUS exam was 
performed for 1 minute following the injection of Definity. The scan data contains the 
grayscale image on the right hand side and the contrast enhanced image on the left side, as 
shown in figure below. The HCC is marked using a red circle in figures 3.1, 3.2 and 3.3. 
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Figure 3.1: CEUS scan data of a patient prior to TACE procedure. 
  
Figure 3.2: CEUS scan data of a patient 2 weeks post TACE procedure. 
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Figure 3.3: CEUS scan data of a patient 4 weeks post TACE procedure. 
 
3.3 CEUS Data Analysis 
The offline processing of the CEUS data was performed using MATLAB (Version R2013a, 
Mathworks Inc.) license obtained via Drexel University. The CEUS data processing may 
be divided into two parts: 
1. Motion Compensation 
2. Parametric Imaging 
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3.3.1 Motion Compensation 
The CEUS scans performed on the patients suffer from motion artifacts due to respiration, 
movement of the patient as well as the transducer. Performing motion compensation on the 
data will not only reduce motion artifacts, but also aid in better visualization of the tumor. 
Maximum intensity projection algorithm was used to develop an automated technique for 
motion compensation. For implementation of the motion compensation, an algorithm was 
developed in MATLAB (R2013a, The Mathworks Inc., Natick, MA) in the ultrasound 
research laboratory of Thomas Jefferson University Hospital by Dr. Jaydev K. Dave and 
his team. The working of this algorithm is described in the following sections. 
 
3.3.1.1 Creating a database of individual frames 
The scan data is available in Windows media audio/video (.wmv) file format. The data is 
first organized into a suitable format in order to process it. This is done by splitting the 
video data into individual JPEG (.jpg) frames (US scanner sampling rate = 9Hz, 10Hz, 
11Hz, 12Hz, 14Hz) using a free Video to JPG Converter v.5.0.23 build 320, an open source 
software developed by DVDVideoSoft Ltd. Certain frames were eliminated from the 
processing. These include the scout frames. Scout frames are the initial frames acquired by 
US technologist while trying to locate the liver mass. These frames may not be present in 
the later part of the scan. Thus, if a kernel is selected in any of these frames, there would 
be no region that corresponds to the kernel in the successive frames.  
During an ultrasound scan, the sonographer may move the transducer back and forth to 
obtain a better visualization of the structures in the scanned area. This fluctuation in 
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position of the transducer may cause frames from different scan angles and position to be 
present in the scan data. Such frames, if used, to generate final image may lead to 
misdiagnosis. These frames are identified and removed from the final dataset [34]. The 
final set of frames are numbered starting from 0, for processing convenience using 
Advanced Renamer Version 3.66 an open source software developed by Kim Jensen 
(Denmark). 
 
3.3.1.2 Kernel Selection 
To select the kernel, the first frame from the in-flow of contrast agent is presented to the 
user. The kernel is a group of pixel that is analyzed as a single unit. It would be used to 
track the motion that may produce misalignment in the final image. The kernel selected 
should not coincide with the image borders. It should neither be too large nor too small. 
Very small kernels may result in multiple matches, whereas, very large kernels may affect 
the activity of the motion compensation in consecutive frames [34]. Figure 3.4 shows 
selection of the kernel from the first frame in the contrast inflow period. 
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Figure 3.4: Selection of kernel from the first frame in the contrast inflow period. 
 
3.3.1.3 Calculating the number of iterative steps for each frame 
The algorithm computes the number of iterative steps. It is based on the size of the selected 
kernel, size of individual frames and the overlap percentage, “p”, specified by the user. 
Consider an image with “m” pixel columns and “n” pixel rows. Let “a” and “b”, 
respectively, be the rows and columns of the selected kernel.  After completing an iteration, 
the kernel would have moved through “x” pixel columns or “y” pixel rows to its new 
location corresponding to next iteration. Based on the overlap percentage ‘p’, the total 
number of iterations (N) is given by: 
N=
1
1−
𝑝
100
∗ (
𝑚𝑛
𝑎𝑏
) ………………………….…………… (3.1) 
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Since ‘”p” represents the percentage of overlap of the kernel in between iterations, a 100% 
overlap value indicates no motion of the kernel from its previous iteration to the new 
position for the next iteration [34]. 
 
3.3.1.4 Scanning successive frames 
In each successive frame, the algorithm scans from left to right and top to bottom to identify 
the best match for the selected kernel. Sum of absolute difference (SAD) is used to calculate 
the best match for the kernel. For a kernel with “m” rows and “n” columns, SAD is 
calculated by equation 
SAD = ∑ ∑ | 𝑘𝑟𝑛(𝑖, 𝑗) − 𝑖𝑚𝑔(𝑖, 𝑗)|𝑛𝑗=1
𝑚
𝑖=1 …………………………………… (3.2) 
where, krn (i, j) and img (i, j) are respectively the pixel values of the kernel and the portion 
of image being scanned during a particular iteration, at location (i, j).  SAD values are 
computed for every iteration in each frame and stored in an array. The minimum value of 
the SAD values corresponds to the best match to the selected kernel. The coordinates of 
the best match in the particular frame is selected and the process is repeated for all the 
frames [34]. 
 
3.3.1.5 Calculating the displacement to evaluate the motion in successive frames with 
respect to the first frame 
The co-ordinates of the best match obtained are compared to the original kernel co-
ordinates. The displacement is calculated using equation  
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D = √(𝑦2 − 𝑦1)2 + (𝑥2 − 𝑥1)2 
Where, 
(x1, y1) = co-ordinates of the kernel in the first frame 
(x2, y2) = co-ordinates of the best match to the kernel 
The displacement as well as the co-ordinates of the best match are saved for further 
processing [34]. 
 
3.3.1.6 Decision-making criteria 
This step is to identify the noisy frames and eliminate them from further processing.  This 
is achieved by calculating the reliability parameter (RP) for every frame.  
RP = 
|𝐸[𝑆𝐴𝐷]− 𝑆𝐴𝐷𝑖|
𝐸[𝑆𝐴𝐷]
………………………………………. (3.3) 
Where E[SAD] is the mean of all SAD values and “i” denotes the SAD value of the ith 
frame. In certain frames, the region of interest that was supposed the match the kernel may 
extend beyond the image boundaries as seen in Figure 3.5. 
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Figure 3.5: Example showing kernel match extending beyond image borders. 
 The RP, in such cases, is a useful parameter to identify as well as eliminate these frames. 
Higher RP values would indicate good match (low SAD values) and vice versa [34].  
A threshold RP value is set for each case that helps decide whether to accept or reject the 
frame under consideration. Figure 3.6 shows box plot of RP values of the 16 CEUS scans. 
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Figure 3.6: Reliability Parameters for 14 Patients 
 
3.3.1.7 Final image reconstruction 
The frames that have RP values greater than the threshold are selected and retained for the 
image construction process. Starting from the second frame, each successive frame is 
aligned with respect to the first frame. The alignment is based on the displacement 
calculated by the algorithm in section 3.3.1.5. The stored co-ordinates of the kernel matches 
in each frame is compared with the kernel co-ordinates in the first frame, and is then 
superimposed onto the first frame. The final image is then displayed after processing all 
the selected frames [34]. Figure shows the complete flowchart of the motion compensation 
algorithm. 
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Figure 3.7: Motion Compensation Algorithm Flowchart. Reproduced from [34] 
Figures 3.8, 3.9 and 3.10 show the final motion compensated image. The red circle 
indicates the tumor location. 
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Figure 3.8: Final reconstructed image (Prior to TACE) 
 
Figure 3.9: Final reconstructed image (2 weeks post TACE) 
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Figure 3.10: Final reconstructed image (4 weeks post TACE) 
The image sequence produced during motion compensation were saved and numbered 
according to their original frame number. This helps to keep record of the images that were 
discarded due to presence of excessive noise. 
 
3.3.2 Parametric Imaging 
Parametric imaging was performed on the motion compensated sequences of each lesion. 
Time intensity curves were generated on a pixel-by-pixel basis to create parametric images 
showing maximum signal intensity (MAX), time to peak (TTP), Perfusion (PER) and area 
under curve (AUC). Parametric imaging was performed using MATLAB (R2013a, 
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Mathworks Inc., Natick, MA). The algorithm of parametric imaging is explained in the 
following sections. 
 
 3.3.2.1 Creating a file list 
The sequence of the motion compensated images are imported into MATLAB and 
converted to gray scale. During motion compensation, these images were saved and 
numbered according to their frame number. The frame number was extracted from the file 
name and saved into a matrix. The image sequences were all saved into a single array. 
 
3.3.2.2. Calculating the parameters 
The array containing the image sequence is scanned one pixel at a time to determine when 
the peak intensity occurs. The maximal intensity is calculated and the frame number (3rd 
dimension of the array) is determined. This frame number is then divided by the US scanner 
sampling frequency to compute the time of peak intensity.  
Maximum intensity, time to peak, perfusion and area under curve are computed and 
parametric images are generated as shown in the figures below. 
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Figure 3.11: Parametric image showing the maximum intensity 
 
Figure 3.12: Parametric image showing the time to peak 
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Figure 3.13: Parametric image showing Perfusion 
 
    Figure 3.14: Parametric image showing area under curve 
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3.3.2.3 Evaluate the four parameters in selected region of interest (ROI) 
The user is presented with an image to select the tumor on the B-mode side of the image. 
This ROI is then translated onto the contrast enhanced side of the image. The time intensity 
parameters of the ROI are saved. 
 
Figure 3.15: User selected ROI in B-mode 
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Figure 3.16: Translated ROI from B-mode to contrast enhanced mode 
 
Parametric imaging was performed on the entire dataset. The values are average over tumor 
and expressed normalized relative to baseline. Results were then grouped by MRI findings 
and compared at each time point. The statistical analysis was performed using SPSS 
Statistics 23 (IBM, Armonk, NY). 
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4. RESULTS 
 
Twenty one patients scheduled for transarterial chemoembolization using drug-eluting 
beads were approached for this study. Fourteen patients (11 males and 3 females) with 16 
lesions were enrolled in the study. Six lesions were excluded due to excessive motion 
making it difficult to identify the tumor ROI. A total of three CEUS scans, pre TACE 
procedure, 2weeks post TACE and 4 weeks post TACE, were performed on each lesion. 
One lesion had two scans, as the patient was unable to attend the follow up 2 weeks post 
TACE. Thus, this study involved analysis of 10 lesions, 29 CEUS scans for analysis. The 
flow diagram below summarizes the patient enrollment as well as the data processing for 
the study. 
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Figure 4.1: Flow diagram showing patient enrollment and data processing for the study. 
 
4.1 Motion Compensation  
Motion compensation was successfully performed on the CEUS data. The new sequence 
of images were saved and numbered according to their initial frame number. This was done 
to maintain a track of the timeline of the frame while generating time-intensity curves. 
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The figures below show selected frames from a sequence of motion compensated images. 
The outcomes of the patients were divided into three groups: 1=complete response, 
2=partial response and 3= no response. 
 
4.1.1 Complete Response 
 
Figure 4.2: Image after motion compensation, pre-treatment scan 
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Figure 4.3: Image after motion compensation, 2 weeks post treatment scan 
 
 
Figure 4.4: Image after motion compensation, 4 weeks post treatment scan 
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4.1.2 Partial Response 
 
 Figure 4.5: Image after motion compensation, pre-treatment scan 
  
 
Figure 4.6: Image after motion compensation, 2 weeks post treatment scan 
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Figure 4.7: Image after motion compensation, 4 weeks post treatment scan 
 
4.1.3 No Response 
 
Figure 4.8: Image after motion compensation, pre-treatment scan 
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Figure 4.9: Image after motion compensation, 2 weeks post treatment scan 
 
 
Figure 4.10: Image after motion compensation, 4 weeks post treatment scan 
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4.2 Parametric Imaging 
Parametric Imaging was successfully performed in 10 the lesions. The tumor ROIs were 
marked and the parameters maximum intensity (MAX), time to peak (TTP), perfusion 
(PER) and area under curve (AUC) were extracted from the generated time-intensity 
curves. Figures below show parametric images from the three groups: complete response, 
partial response and no response.  
 
4.2.1 Parametric Images of a complete response case 
4.2.1.1 Complete Response- Maximum Intensity 
 
Figure 4.11: Maximum Intensity of Image Sequence – pre treatment 
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Figure 4.12: Maximum Intensity of Image Sequence – 2 weeks post treatment 
 
Figure 4.13: Maximum Intensity of Image Sequence – 4 weeks post treatment 
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4.2.1.2 Complete Response- Time to peak 
 
Figure 4.14: Time to peak of Image Sequence – pre treatment 
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Figure 4.15: Time to peak of Image Sequence – 2 weeks post treatment 
 
Figure 4.16: Time to peak of Image Sequence – 4 weeks post treatment 
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4.2.1.3 Complete Response- Perfusion 
 
Figure 4.17: Perfusion– pre treatment 
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Figure 4.18: Perfusion– 2 weeks post treatment 
 
Figure 4.19: Perfusion– 4 weeks post treatment 
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4.2.1.4 Complete Response- Area under curve 
 
Figure 4.20: Area under curve – pre treatment 
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Figure 4.21: Area under curve – 2 weeks post treatment 
 
Figure 4.22: Area under curve – 4 weeks post treatment 
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4.2.2 Parametric Images of a partial response case 
4.2.2.1 Partial Response- Maximum Intensity 
 
Figure 4.23: Maximum Pixel Intensity of image sequence – pre treatment 
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Figure 4.24: Maximum Pixel Intensity of image sequence – 2 weeks post treatment 
 
Figure 4.25: Maximum Pixel Intensity of image sequence – 4 weeks post treatment 
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4.2.2.2 Partial Response- Time to peak 
Figure 4.26: Time to peak of image sequence – pre treatment 
 
 
 Figure 4.27: Time to peak of image sequence – 2 weeks post treatment  
55 
 
 
 Figure 4.28: Time to peak of image sequence – 4 weeks post treatment  
4.2.2.3 Partial Response- Perfusion 
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Figure 4.29: Perfusion – pre treatment 
 
 
Figure 4.30: Perfusion – 2 weeks post treatment 
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Figure 4.31: Perfusion – 4 weeks post treatment 
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4.2.2.4 Partial Response- Area under curve 
 
Figure 4.32: Area under curve – pre treatment 
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Figure 4.33: Area under curve – 2 weeks post treatment 
 
Figure 4.34: Area under curve – 4 weeks post treatment 
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4.2.3 Parametric Images of a no response case 
4.2.3.1 No Response- Maximum Intensity 
 
Figure 4.35: Maximum pixel intensity of image sequence– pre treatment 
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Figure 4.36: Maximum pixel intensity of image sequence– 2 weeks post treatment 
 
Figure 4.37: Maximum pixel intensity of image sequence– 4 weeks post treatment 
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4.2.3.2 No Response- Time to peak 
 
Figure 4.38: Time to peak of image sequence– pre treatment 
 
63 
 
 
Figure 4.39: Time to peak of image sequence– 2 weeks post treatment 
 
Figure 4.40: Time to peak of image sequence– 4 weeks treatment 
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4.2.3.3 No Response- Perfusion 
 
Figure 4.41: Perfusion– pre treatment 
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Figure 4.42: Perfusion– 2 weeks post treatment 
 
Figure 4.43: Perfusion- 4 weeks post treatment 
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4.2.3.4 No Response- Area under curve 
 
Figure 4.44: Area under curve– pre treatment 
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Figure 4.45: Area under curve– 2 weeks post treatment 
 
Figure 4.46: Area under curve– 4 weeks post treatment 
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4.3 Parametric Data of the ROI 
The parametric data of all the patients were tabulated and normalized relative to baseline. 
Table 4.1, 4.2 and 4.3 show the extracted parametric values as well as the normalized 
values.  
Table 4.1: Parametric values of patients with complete response 
 MAX TTP PER AUC NMAX NTTP NPER NAUC 
Complete Response       
         
TACE01             
Pre TACE 
0.435 22.793 0.036 0.004 1.000 1.000 1.000 1.000 
After 2weeks 
0.326 6.559 0.072 0.436 0.749 0.288 2.003 121.139 
After 4weeks 
0.666 7.825 0.101 0.008 1.531 0.343 2.809 2.250 
TACE10             
Pre TACE 
0.713 47.248 0.016 0.299 1.000 1.000 1.000 1.000 
After 2weeks 
0.312 13.904 0.032 0.007 0.438 0.294 2.071 0.022 
After 4weeks 
0.446 24.351 0.022 0.003 0.625 0.515 1.419 0.008 
         
TACE11 Lesion 1           
Pre TACE 
0.873 10.473 0.085 0.007 1.000 1.000 1.000 1.000 
After 2weeks 
0.683 14.174 0.051 0.004 0.782 1.353 0.601 0.600 
After 4weeks 
0.499 4.443 0.114 0.020 0.572 0.424 1.344 3.062 
         
TACE11 Lesion 2           
Pre TACE 
0.404 10.161 0.043 0.008 1.000 1.000 1.000 1.000 
After 2weeks 
0.662 9.418 0.086 0.063 1.637 0.927 1.977 7.911 
After 4weeks 
0.386 14.354 0.027 0.043 0.956 1.413 0.628 5.468 
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Table 4.2: Parametric values of patients with partial response 
 MAX TTP PER AUC NMAX NTTP NPER NAUC 
Partial Response        
         
TACE02             
Pre TACE 
0.720 7.339 0.101 0.015 1.000 1.000 1.000 1.000 
After 2weeks 
0.395 15.904 0.026 0.003 0.549 2.167 0.259 0.212 
After 4weeks 
0.288 36.847 0.008 0.224 0.401 5.021 0.078 14.821 
         
TACE06             
Pre TACE 
0.615 22.485 0.044 0.005 1.000 1.000 1.000 1.000 
After 2weeks 
- - - - - - -  
After 4weeks 
0.057 3.245 0.017 0.002 0.092 0.144 0.397 0.444 
         
TACE07             
Pre TACE 
0.712 15.287 0.105 0.019 1.000 1.000 1.000 1.000 
After 2weeks 
0.692 41.037 0.028 0.486 0.972 2.685 0.264 25.595 
After 4weeks 
0.663 10.372 0.083 12.035 0.931 0.679 0.787 633.405 
         
TACE08             
Pre TACE 
0.707 49.124 0.031 1.490 1.000 1.000 1.000 1.000 
After 2weeks 
0.788 11.767 0.069 0.012 1.115 0.240 2.231 0.008 
After 4weeks 
0.453 12.536 0.039 0.003 0.640 0.255 1.269 0.002 
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Table 4.3: Parametric values of patients with no response 
 MAX TTP PER AUC NMAX NTTP NPER NAUC 
No Response        
         
TACE05             
Pre TACE 
0.209 7.556 0.028 0.003 1.000 1.000 1.000 1.000 
After 2weeks 
0.539 26.967 0.061 1.728 2.578 3.569 2.199 595.828 
After 4weeks 
0.365 33.282 0.019 0.006 1.748 4.404 0.679 2.138 
         
TACE14             
Pre TACE 
0.793 9.843 0.083 0.015 1.000 1.000 1.000 1.000 
After 2weeks 
0.544 26.819 0.035 0.610 0.687 2.725 0.418 41.463 
After 4weeks 
0.337 25.377 0.017 0.005 0.425 2.578 0.207 0.333 
   
Average and standard deviation of the normalized values are computed. Table 4.4 and 4.5 
show the calculated average and standard deviation of the three groups. 
 
Table 4.4: Average of the normalized data 
 
Average 
MAX 
Average 
TTP Average PER Average AUC 
Complete Response     
Pre TACE 
1.000 1.000 1.000 1.000 
After 2weeks 
0.902 0.716 1.663 32.418 
After 4weeks 
0.921 0.674 1.550 2.697 
     
Partial Response     
Pre TACE 
1.000 1.000 1.000 1.000 
After 2weeks 
0.879 1.697 0.918 8.605 
After 4weeks 
0.516 1.525 0.633 162.168 
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No Response     
Pre TACE 
1.000 1.000 1.000 1.000 
After 2weeks 
1.632 3.147 1.308 318.645 
After 4weeks 
1.087 3.491 0.443 1.236 
 
 
Table 4.5: Standard deviation of the normalized data 
 Stdev MAX Stdev TTP Stdev PER Stdev AUC 
Complete Response     
Pre TACE 
0.000 0.000 0.000 0.000 
After 2weeks 
0.618 0.533 0.823 4.398 
After 4weeks 
0.208 0.546 0.437 2.736 
     
Partial Response     
Pre TACE 
0.000 0.000 0.000 0.000 
After 2weeks 
0.294 1.288 1.137 14.714 
After 4weeks 
0.356 2.342 0.514 314.233 
     
No response     
Pre TACE 
0.000 0.000 0.000 0.000 
After 2weeks 
1.337 0.597 1.259 391.995 
After 4weeks 
0.936 1.291 0.334 1.276 
 
4.4 Statistical Analysis 
Statistical analysis of the data involved comparing three groups. The data obtained is tested 
for normal distribution. In case of normal distribution ANOVA is used to test significance. 
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In non-normal data, Kruskal-Wallis test is used. SPSS Statistics 23 (IBM, Armonk, NY) 
was used to perform statistical tests. 
 
4.4.1 Two weeks post TACE 
In the post 2 week dataset, it was seen that maximum intensity, perfusion and area under 
did not show normal distribution, whereas time to peak was normal distribution. Table 4.6 
shows the p values for four parameters, maximum intensity, and time to peak, perfusion 
and area under curve, 2 weeks post TACE. The analysis performed showed a significant 
value in case of time to peak (p=0.047), but no significant value for maximum intensity, 
perfusion and area under curve.  
Table 4.6: p-values for parameters, 2 weeks post TACE 
Parameter p value 
MAX 0.844 
TTP 0.047 
PER 0.794 
AUC 0.184 
  
The ANOVA for time to peak results do not provide information about the significance 
among the groups. Thus, pairwise comparison, Fisher’s LSD test was performed. Table 4.7 
show the result of the LSD test performed on the post 4 week time to peak data. 
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Table 4.7: LSD comparison of TTP data 2 weeks post treatment 
Response Type p-value 
Complete response vs Partial Response 0.188 
Complete response vs No Response 0.018 
Partial response vs No Response 0.116 
 
 
4.4.2 Four weeks post TACE 
Table 4.8 shows the p values for four parameters, maximum intensity, and time to peak, 
perfusion and area under curve, 4 weeks post TACE. The analysis performed showed 
significant value no significant value for any of the four parameters. 
Table 4.8: p-values for parameters, 4 weeks post TACE 
Parameter p value 
MAX 0.403 
TTP 0.338 
PER 0.158 
AUC 0.779 
 
Significant difference was observed only in time to peak, 2 weeks post TACE (p=0.047). 
On performing pairwise comparison, significant difference is observed between complete 
response and no response groups (p=0.018).  
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Figure 4.47: Average of normalized maximum intensity a) 2 weeks post TACE, b) 4 weeks post 
TACE 
                               
 
Figure 4.48: Average of normalized time to peak a) 2 weeks post TACE, b) 4 weeks post TACE 
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Figure 4.49: Average of normalized perfusion a) 2 weeks post TACE, b) 4 weeks post TACE 
 
Figure 4.50: Average of normalized area under curve a) 2 weeks post TACE, b) 4 weeks post 
TACE 
 
It can be noted from the graphs above, that there is a decrease in the perfusion as well as 
area under the curve value 2 weeks and 4 weeks post treatment in the case of complete 
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significant difference. This may be due to small sample size used for the study, which is 
resulting in low statistical power. 
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5. DISCUSSION 
 
Fourteen patients with 16 lesions were scanned. Out of these 16 lesions, 6 lesions were 
excluded inability to identify tumor. Motion compensation and parametric imaging were 
successfully performed in the 10 lesions. Statistical analysis performed on the parameters 
2 weeks post TACE showed a significant value in case of time to peak (p=0.047), but no 
significant difference in case of MAX, PER and AUC. No significant difference was seen 
in any of the four parameters 4 weeks post TACE. On performing pairwise comparison 
between the three outcome groups, significant difference was seen between complete 
response and no response (p=0.018) in time to peak 2 weeks post TACE. However, there 
was no significant difference between the complete and partial response group (p=0.188) 
and between partial response and no response (p=0.116). Thus, contrast enhanced 
evaluation of transarterial chemoembolization does appear to be an effective follow up 
method 2 weeks post TACE.  
Studies conducted by Kono et al. showed lack of detected contrast agent 2 days post TACE. 
The study was performed on 29 patients who were scheduled for a TACE procedure. The 
authors report that if CEUS performed within days after TACE is as sensitive as they had 
reported in their study, it would prove to be an attractive alternative to contrast enhanced 
CT/MRI [40]. This is because sonography is inexpensive, assessable, and can be performed 
repeatedly at the bedside.  
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In the case of TACE, it is not clear whether residual tumor blood flow detected shortly 
after TACE is an indication of treatment failure, as the chemotherapy in the beads still 
continue to treat residual tumor tissue.  
There were a number of limitations to this study. Firstly, only 10 lesions were used for the 
study. A small sample size results in low statistical power. The statistical power of this 
study was calculated to be 60.23%. This in turn reduces the chances of detecting the true 
effect. Excessive motion artifacts and noise made identification of tumor difficult even 
after motion compensation was performed on the CEUS scans.  
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6. CONCLUSION AND FUTURE WORK 
 
The overall objective of this thesis was to determine the feasibility of using contrast 
enhanced ultrasound for the evaluation of transarterial chemoembolization with drug 
eluting beads. The purpose of the study is to establish whether changes in blood flow 
parameters relative to baseline correlate with effective chemoembolization.  
Performing motion compensation on the CEUS data helps remove the motion artifacts and 
frames plagued with noise. The time intensity curve parameters considered for the study 
were maximum pixel intensity, time to peak, perfusion and area under curve. These 
parameters were averaged over the tumor and expresses normalized relative to baseline. 
Statistical analysis was performed on these datasets and significant difference was 
observed only in the time to peak dataset 2 weeks post TACE procedure. Time to peak 
currently appears to be a good quantitative CEUS parameter to evaluate TACE 
effectiveness. 
The results presented in this study are based on a limited sample size (10 lesions). As this 
was a pilot study, no sample size assessment could be made a priori. The number of subjects 
selected was based on the investigators experience and the norms associated with pilot 
studies conducted in radiology. A similar study conducted on a larger scale with more 
number of patients would increase the statistical power of the study.  
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APPENDIX A: RESULTS: PARAMETRIC IMAGES 
APPENDIX A.1: PATIENT 01 
Pre- treatment 
  
                                (a)                                                                      (b) 
  
                                 (c)                                                                   (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
(a)                                                                  (b)
  
 
 
 
 
 
 
 
 
 
 (a 
                              (c)                                                                      (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) Area 
under Curve 
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4 weeks post TACE 
  
                               (a)                                                                   (b) 
  
                                (c)                                                                  (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.2: PATIENT 02 
Pre-treatment 
 
  
                               (a)                                                               (b) 
  
 
 
 (c)                                                                 (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
 
 
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
         
         
                               (a)                                                                  (b) 
  
                                 (c)                                                                  (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
  
 
 
 
 
  
 
 
 
                              (a)                                                                      (b) 
  
                              (c)                                                                    (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.3: PATIENT 05 
Pre-treatment 
  
 
                               (a)                                                                   (b) 
  
 
                                (c)                                                                   (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
                              (a)                                                                    (b) 
  
                               (c)                                                                    (d)  
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
     
                                     (a)                                                    (b) 
  
                                   (c)                                                                         (d) 
 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.4: PATIENT 06 
Pre-treatment 
  
                               (a)          (b) 
  
         (c)                               (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
 
  
          (a)                                 (b) 
  
          (c)                                         (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.5: PATIENT 07 
Pre-treatment 
 
                              (a)                (b) 
   
                               (c)                                                                 (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
 
                               (a)                                                              (b) 
 
      (c)                                                                       (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
 
                                   (a)                                                                         (b) 
 
               (c)                                                                          (d) 
 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.6: PATIENT 08 
Pre-treatment 
  
                            (a)                                                               (b) 
  
      (c)                                                                  (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 Weeks post TACE 
 
                                 (a)                                                                      (b) 
 
                                  (c)                                                                          (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
  
                    
                              (a)                                                               (b) 
  
                              (c)                                                                (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.7: PATIENT 10 
Pre-treatment 
  
                              (a)                                                             (b) 
  
            (c)          (d) 
 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
          (a)              (b) 
  
         (c)              (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
  
                                  (a)                                                                           (b) 
  
                                (c)                                                                    (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.8: PATIENT 11 Lesion 01 
Pre-treatment 
  
                               (a)                                                                   (b) 
  
  (c)               (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
  (a) (b) 
  
      (c)                                                                       (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
  
                                 (a) (b) 
  
                                   (c)                                                                        (d) 
 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.9: PATIENT 11 Lesion 02 
Pre-treatment 
  
 (a)                                                             (b) 
  
    (c)      (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
                                 (a)            (b) 
  
         (c)                          (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
  
                              (a)                                                                (b) 
  
 (c) (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX A.10: PATIENT 14 
Pre-treatment 
  
      (a)                                                                   (b) 
  
                                 (c)                                                                   (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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2 weeks post TACE 
  
 (a)                                                                       (b) 
  
 (c)                                                                  (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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4 weeks post TACE 
  
 (a)                                                                     (b) 
  
 (c)                                                                (d) 
a) Maximum Pixel Intensity of sequence, b) Time to peak of Sequence, c) Perfusion, d) 
Area under Curve 
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APPENDIX B: Program Code 
APPENDIX B.1: Motion Compensation Code 
%This code has been developed by Dr. Jaydev K. Dave and his team at 
%Ultrasound laboratory (Thomas Jefferson University) 
clear all; 
close all; 
iptsetpref('ImshowBorder','tight'); 
  
%% Build image file list 
TotalNumberofFrames=input('Enter Total Number of Frames in File List ---->'); 
[filename, pathname] = uigetfile('*.*','Select FIRST image file...'); 
cd(pathname); 
filechar = double(filename); 
  
t=1:TotalNumberofFrames;  
  
loc1=find(filechar==48); 
head=filename(1:loc1(2));  
  
loc2=find(filechar==46); 
tail=filename(loc2:end); 
  
numimages=1; 
  
% create file list for first 99 frames 
for i=1:99 
    numimages=numimages+1; 
    if i-1<10 
        fname=[head num2str(0) num2str(i-1) tail]; 
    else 
        fname=[head num2str(i-1) tail]; 
    end 
    filelist{numimages}=fname; 
end 
  
%  %add frames 100-999 
head=filename(1:loc1(1)); 
  
for i=101:TotalNumberofFrames; 
    numimages=numimages+1; 
    if i-1<10 
        fname=[head num2str(0) num2str(i-1) tail]; 
    else 
        fname=[head num2str(i-1) tail]; 
    end 
    filelist{numimages}=fname; 
end 
filelist = filelist'; 
  
%% Reading the first image!! 
img11=imread(filelist{2}); 
114 
 
  
%% Converting the image into suitable form 
img11=im2double(rgb2gray(img11)); 
  
%% Selecting the required size of the image- Ignoring labels at the side 
figure(1) 
imshow(img11) 
[tc,tr]=ginput(1); 
[bc,br]=ginput(1); 
tc=round(tc); 
tr=round(tr); 
br=round(br); 
bc=round(bc); 
img1=img11(tr:br,tc:bc); 
[ori_rows,ori_cols]=size(img1); 
  
%% For the User to select the kernel 
figure(1) 
subplot(2,1,1) 
imshow(img1) 
title('First Image in the series') 
[topcolumn,toprow]=ginput(1); 
[bottomcolumn,bottomrow]=ginput(1); 
topcolumn=round(topcolumn); 
toprow=round(toprow); 
bottomrow=round(bottomrow); 
bottomcolumn=round(bottomcolumn); 
  
%% Making the kernel 
kernel=img1(toprow:bottomrow,topcolumn:bottomcolumn); 
figure(1) 
subplot(2,1,2) 
imshow(kernel) 
title('kernel') 
[kernelrows,kernelcolumns]=size(kernel); 
  
%% Creating the final padded image on which the result will be pasted 
finalrows=ori_rows+ori_rows; 
finalcols=ori_cols+ori_cols; 
final=zeros(finalrows,finalcols); 
startrow=round((ori_rows)/2); 
startcol=round((ori_cols)/2); 
endrow=round((3*ori_rows/2)); 
endcol=round((3*ori_cols/2)); 
  
%% Preparing the Final image with the first image which will be used as reference 
final(startrow:endrow-1,startcol:endcol-1)=img1; 
figure(2) 
imshow(final) 
  
%% Calculating the number of total iterations required 
numberofiterations_rows=ori_rows-kernelrows+1; 
numberofiterations_cols=ori_cols-kernelcolumns+1; 
number=numberofiterations_rows*numberofiterations_cols; 
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%% Change Made 
alpha_matrix=zeros(numimages,1); 
  
%% Reading the next images from the sequences 
for k=2:numimages 
     
    %% Reading the first image 
    img22=imread(filelist{k}); 
     
    %% Converting the image into suitable form 
    img22=im2double(rgb2gray(img22)); 
     
    %% Selecting the required size of the image- Ignoring labels at the side 
    img2=img22(tr:br,tc:bc); 
     
    %% Creating the array to store the result 
    store=zeros(number,3); 
    counter=0; 
     
    %% SAD and storing the Result 
    for i=1:numberofiterations_rows 
        for j=1:numberofiterations_cols 
            counter=counter+1; 
            temp=abs(img2(i:i+kernelrows-1,j:j+kernelcolumns-1)-kernel); 
            tempsum=sum(sum(temp)); 
            store(counter,:)=[i,j,tempsum]; 
        end 
    end 
     
    %% Finding the best match and calculating the displacement with respect 
    %% to the first image 
    minimumerr=min(store(:,3)); 
    SAD_mean=mean(store(:,3)); 
    MSAD=minimumerr; 
    alpha_image=(SAD_mean-MSAD)/SAD_mean 
    alpha_matrix(k)=alpha_image; 
    if alpha_matrix(k)>=0.63 
    loc=find(store(:,3)==minimumerr); 
    matchrow=store(loc,1); 
    matchcol=store(loc,2); 
    displacement_row=toprow-matchrow; 
    displacement_col=topcolumn-matchcol; 
     
    %% Calculating the place where the next image has to be pasted with displacement 
    newstartrow=startrow+displacement_row; 
    newstartcol=startcol+displacement_col; 
    newendrow=newstartrow+ori_rows; 
    newendcol=newstartcol+ori_cols; 
    for i=newstartrow:newendrow-1 
        for j=newstartcol:newendcol-1 
            ii= (i-displacement_row)-startrow+1; 
            jj=(j-displacement_col)-startcol+1; 
            if final(i,j)<img2(ii,jj) 
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                final(i,j)=img2(ii,jj); 
            else 
            end 
        end 
    end 
    figure(3) 
    imshow(final) 
    text(225,100,['Image number being added : ', num2str(k)],'BackgroundColor',[.7 .9 .7]) 
%    if alpha_matrix(k)>=0.69 
    saveas(gcf,strcat('Image_added',num2str(k),'.jpg')); 
   end 
   end 
% end 
figure(4) 
imshow(final) 
text(225,100,['Final Image!! Images Iterated : ', num2str(k)],'BackgroundColor',[.7 .9 .7]) 
finalf=final(startrow:endrow-1,startcol:endcol-1); 
newnf=zeros(size(img11)); 
for i=1:434 
    for j=1:532 
        if i>=tr && i<=br && j>=tc && j<=bc 
            newnf(i,j)=finalf(i-tr+1,j-tc+1); 
        else 
            newnf(i,j)=img11(i,j); 
        end 
    end 
end 
  
figure(5) 
imshow(newnf) 
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APPENDIX B.2: Parametric Imaging Code 
clear all; 
close all; 
FPS=input('Frames per second---->'); 
LeadTime=input('Enter Lead Time------->'); 
dT=1/FPS; 
  
% to select folder path 
[filename, pathname] = uigetfile('*.*','Select FIRST image file...'); 
cd(pathname); 
filechar = double(filename); 
  
%make a list of files with jpg extension and extract the frame number 
from 
%the file name 
files=dir('*.jpg'); 
for i=1:numel(files) 
    numberstr=regexp(files(i).name,'(\d*).jpg','tokens'); 
    numberstr=numberstr{1}; 
    number(i)=str2double(numberstr); 
end 
number=sort(number);%to sort the file numbers in ascending order 
%to make a file list, this is the head and tail of the file name  
loc1=find(filechar==48); 
head1=filename(1:loc1(3));  
head2=filename(1:loc1(2)); 
head3=filename(1:loc1(1)); 
loc2=find(filechar==46); 
tail=filename(loc2:end); 
  
numimages=0; 
  
% create file list for all the frames 
for i=1:max(size(number)); 
    numimages=numimages+1; 
    if number(i)<10 
        fname=[head1 num2str(number(i)) tail]; 
          
     elseif number(i)<100 
          
        fname=[head2 num2str(number(i)) tail]; 
    else 
         
        fname=[head3 num2str(number(i)) tail]; 
    end 
         
    filelist{numimages}=fname; 
end 
%% to select the required size of the images 
%reading the first image of the filelist 
img1=imread(filelist{1}); 
%converting it to a suitable form 
img1=im2double(rgb2gray(img1)); 
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%selecting required size of the image 
imshow(img1) 
figure(1) 
imshow(img1) 
[tc,tr]=ginput(1); 
[bc,br]=ginput(1); 
tc=round(tc); 
tr=round(tr); 
br=round(br); 
bc=round(bc); 
imgtemp=img1(tr:br,tc:bc); 
%% to read the next images in the file list and selecting the required 
size 
for j=1:max(size(filelist)); 
    j 
    img22=imread(filelist{j}); 
    img22=im2double(rgb2gray(img22)); 
    img2=img22(tr:br,tc:bc); 
    img(:,:,j)=img2; 
end 
  
%% Calculating the parameters 
% Run through array one pixel at a time and determine at which peak 
(3'rd dimension) highest intensity occurs 
  
MatrixDem = size(img); 
% Move through each row  
for Row = 1:MatrixDem(1); 
    % Move through each column   
  for Column = 1:MatrixDem(2); 
%calculate maximal intensity for pixel and determine frame number         
[C,I]=max(img(Row,Column,:)); 
I1= number(I);%number(I) takes in the actual frame number from the 
image file name 
TimeToPeakFrames(Row,Column) = I1; 
TimeToPeak(Row,Column) = (TimeToPeakFrames(Row,Column)+ LeadTime)/FPS; 
MaxPeak(Row,Column) = C;   
end 
end 
% calculate Perfusion rate  
for Row = 1:MatrixDem(1); 
  for Column = 1:MatrixDem(2); 
Perfusion(Row,Column)=MaxPeak(Row,Column)/TimeToPeak(Row,Column); 
  end 
end 
  
% Run though image sequence and calculate area under curve for each 
pixel 
for Row = 1:MatrixDem(1);   
  for Column = 1:MatrixDem(2); 
AreaUnderCurve(Row,Column)=sum(img(Row,Column,1:I)*dT); 
  end 
end 
  
% Save data sets in folder with stored frames 
save TimeToPeak 
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save MaxPeak 
save Perfusion 
save AreaUnderCurve 
  
% Check results by examining images 
figure(2) 
imagesc(MaxPeak) 
title('Maximum Pixel Intensity of Image Sequence') 
colorbar 
saveas(gcf,'max.jpg'); 
  
figure(3) 
imagesc(TimeToPeak) 
title('Time to Peak of Image Sequence') 
colorbar 
saveas(gcf,'ttp.jpg'); 
  
figure(4) 
imagesc(Perfusion,[0 0.003]) 
title('Perfusion') 
colorbar 
saveas(gcf,'per.jpg'); 
  
figure(5) 
imagesc(AreaUnderCurve) 
title('Area Under Curve') 
colorbar 
saveas(gcf,'auc.jpg'); 
  
save figure2 
save figure3 
save figure4 
save figure5 
%% Evaluate all 4 parameters in a selected ROI 
%Select Tumor Region of Interest 
Frames=input('Frames ='); %this is to selected the frame that will be 
displayed to select the ROI 
image=img(:,:,Frames); 
figure(6) 
imshow(image); 
title(['Select Tumor ROI']) 
h=imfreehand 
pos=getPosition(h); 
BW=createMask(h); 
s = regionprops(BW, 'Centroid'); 
center_x = s.Centroid(1) %acquire X position of the center mass  
center_y = s.Centroid(2) %acquire Y position of the center mass 
%use ginput to get the coordinates of the midpoint of the image 
[m1 m2]=ginput(1); 
%[r1 r2]=ginput(1); 
[j l]=size(image); 
d=abs(l-center_x); 
p=abs(m1-center_x); 
rowsToShift = 0; 
columnsToShift = round(d+p);%round(l-(2*d));% round(d+p); 
% BW2 = imtranslate(BW, [rowsToShift columnsToShift]); 
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BW2 = circshift(BW, [rowsToShift columnsToShift]); 
figure(7) 
  
imshow(BW2); 
%Determine Size of ROI's 
ROI=MaxPeak(BW2); 
% ROI=MaxPeak(h) 
V1Size=size(ROI);  
V1=V1Size(1)*V1Size(2);  
%Set data set ROI's 
AreaUnderCurveROI=AreaUnderCurve(BW2); 
MaxPeakROI=MaxPeak(BW2); 
TimeToPeakROI=TimeToPeak(BW2); 
PerfusionROI=Perfusion(BW2); 
  
% Calculate 4 parameter values in ROI 
Max=sum(sum(MaxPeakROI,1)); 
TTP=sum(sum(TimeToPeakROI,1)); 
Per=sum(sum(PerfusionROI,1)); 
AUC=sum(sum(AreaUnderCurveROI,1)); 
  
% Normalize values by number of ROI pixels 
AUC=AUC/V1; 
Max=Max/V1; 
TTP=TTP/V1; 
Per=Per/V1; 
  
% Write Results 
Max=[Max] 
TTP=[TTP] 
PER=[Per] 
AUC=[AUC] 
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Appendix C: Copyright Permission 
 
 
 
 
 
 
122 
 
Appendix D: List of software used 
 
 
 
 
1. Matlab R2013a (The Mathworks Inc., Natick WA)  
 
Purpose: To process ultrasound data, perform motion compensation and parametric 
imaging 
 
License: Drexel University  
 
 
2. SPSS Statistics 23  (IBM, Armonk, NY)  
 
Purpose: To perform statistical analysis 
 License: Drexel University  
 
3. Microsoft Office 2013 (Microsoft Corporation, Redmond, WA)  
 
Purpose: For publishing, data handling and presentations. 
License: Drexel University  
 
4.  Video to JPG Converter v.5.0.23 build 320 (DVDVideoSoft Ltd, New Zealand) 
Purpose: For converting CEUS data into individual JPG frames 
License: Open Source 
 
5.  Advanced Renamer Version 3.66 (Kim Jensen, Copenhagen, Denmark) 
Purpose: For naming JPG files 
License: Open Source 
 
